The combination therapy significantly reduced tumor growth compared to control mice and those receiving monotherapy of PD-1 antibody (Con vs. anti-PD-L1, p = 0.0054; Con vs. shMYOF, p = 0.0002; Con vs. shMYOF + anti-PD-L1, p < 0.0001; anti-PD-L1 vs. shMYOF + anti-PD-L1, p = 0.0388) (Figure 8B). This evidence concerns the gene PDCD1 and neoplasm.